Hosted on MSN2h
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Two Hutchinson doctors are on a mission to save sight and change lives in Guatemala
When someone asks where you plan on traveling this year, odds are good Guatemala is not on the itinerary. But for nearly three decades, that’s exactly what two local doctors have been doing, ...
J.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14)
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...
MSD commences Phase III trial of DLBCL treatment
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
The Drug Industry Is Having Its Own DeepSeek Moment
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.